Plus Therapeutics (PSTV) Return on Equity (2011 - 2026)

Plus Therapeutics (PSTV) has 16 years of Return on Equity data on file, last reported at 0.02% in Q1 2026.

• Return on Equity for Q1 2026 came in at 0.02%, down 3.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.02% (down 3.0% YoY), and the FY2025 annual result was 0.06%, up 4.0% from the prior year.
• Return on Equity rose to 0.02% in Q1 2026 per PSTV's latest filing, from 0.03% in the prior quarter.
• Over five years, Return on Equity peaked at 0.04% in Q1 2024 and troughed at 0.21% in Q4 2023.
• A 5-year average of 0.02% and a median of 0.02% in 2022 frame the typical range for Return on Equity.
• The sharpest annual moves came in 2023 and 2024: Return on Equity retreated 19 bps in 2023, then rose 23 bps in 2024.
• A 5-year view of Return on Equity shows it stood at 0.02% in 2022, then slumped by 821 bps to 0.21% in 2023, then soared by 110 bps to 0.02% in 2024, then plunged by 268 bps to 0.03% in 2025, then surged by 33 bps to 0.02% in 2026.
• Business Quant data shows PSTV's Return on Equity at 0.02% in Q1 2026, 0.03% in Q4 2025, and 0.03% in Q3 2025.